Protocol Ledger

NCT04879329 · Phase II · RECRUITING

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Interventional Phase II clinical trial protocol NCT04879329 sponsored by Pfizer in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-05-03 Enrollment: 372 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04879329
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)372 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04879329
Protocol FieldVerified Registry Value
NCT IdentifierNCT04879329
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment372 participants (ESTIMATED)
Registered Start Date2022-05-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04879329
Hospital Research SiteLocationSite Profile
Banner MD Anderson Cancer CenterGilbert, AZOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI